ANALYSIS OF THE IMMUNE RESPONSE IN VISCERAL LEISHMANIASIS

使用特定抗原的疫苗接种在利什曼病中未获成功 由于对免疫事件的了解不足，导致 疾病。我们正在寻找在小鼠模型中的最新发现 利什曼病将研究人类对感染的细胞反应 在体外和体内都有。瓦拉纳西制定了一项临床方案， 印度将研究期间获得的人骨髓和脾抽提物 内脏利什曼病的常规临床评价。Dr。 印度实验室的免疫生物学家Kalpana Pai访问了FDA 在印度启动其他免疫研究的实验室为期3个月 人口。该集团位于巴西维托利亚，正在寻找潜在的 影响感染免疫反应评估的遗传因素 黑素瘤家系细胞因子基因启动子区的多态性 阿扎尔。在这里的实验室里，我们已经开始观察体外培养 对感染前鞭毛体和无鞭毛体的反应 巨噬细胞和巨噬细胞样细胞中的干扰素-γ受体激活途径 细胞。

Vaccination using defined antigens has been unsuccessful in leishmaniasis due to an inadequate understanding of the immune events leading to disease. We are pursing recent findings in the mouse model of leishmaniasis to investigate the cellular response to infection in humans both in vitro and in vivo. A clinical protocol is in place in Varanasi, India to study human bone morrow and splenic aspirates obtained during routine clinical evaluation of patients with visceral leishmaniasis. Dr. Kalpana Pai, an Immunobiologist in the Indian Laboratory visited the FDA Laboratory for 3 months to initiate other immune studies in the Indian population. The group in Vitoria, Brazil is looking at the potential for genetic factors to influence the immune response to infection evaluating polymorphisms in cytokine gene promoter regions in families with kala- azar. In the Laboratory here we have begun to look at the in vitro response to infection with promastigotes and amastigotes by evaluating the IFNgamma receptor activation pathway in macrophages and macrophage-like cells.